Black Titan (NASDAQ:BTTC – Get Free Report) and CI&T (NYSE:CINT – Get Free Report) are both small-cap technology companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation.
Volatility & Risk
Black Titan has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500. Comparatively, CI&T has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500.
Analyst Ratings
This is a summary of recent ratings and recommmendations for Black Titan and CI&T, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Black Titan | 1 | 0 | 0 | 0 | 1.00 |
| CI&T | 1 | 3 | 7 | 0 | 2.55 |
Earnings and Valuation
This table compares Black Titan and CI&T”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Black Titan | $2.18 million | 2.46 | -$4.71 million | ($2.95) | -0.17 |
| CI&T | $489.65 million | 0.82 | $40.62 million | $0.29 | 10.28 |
CI&T has higher revenue and earnings than Black Titan. Black Titan is trading at a lower price-to-earnings ratio than CI&T, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Black Titan and CI&T’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Black Titan | N/A | N/A | N/A |
| CI&T | 6.79% | 11.69% | 6.51% |
Institutional & Insider Ownership
92.4% of CI&T shares are held by institutional investors. 53.7% of Black Titan shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
CI&T beats Black Titan on 11 of the 14 factors compared between the two stocks.
About Black Titan
Titan Pharmaceuticals, Inc. is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.
About CI&T
CI&T, Inc. provides strategy, design and software engineering services to enable digital transformation. The firm’s solutions and services include Digital Strategy, Customer-Centric Design and Top-of-the-Line Software Engineering. The company was founded by Cesar Nivaldo Gon, Bruno Guiçardi Neto and Fernando Matt Borges Martins on June 7, 2021 and is headquartered in Sao Paulo, Brazil.
Receive News & Ratings for Black Titan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Black Titan and related companies with MarketBeat.com's FREE daily email newsletter.
